

Cathryn,

Many thanks for sending CCC the NICE Assessment Report re the use of oxaliplatin and capecitabine in the adjuvant treatment of colorectal cancer. In terms of our response: CCC feels the document is very fair and balanced. We have one or two comments though.

While, as is mentioned on page 22 of the Assessment Report, both the X-Act and MOSAIC trials included some - but by no means all - patients of a younger age range for colorectal cancer, it should be remembered that age is not the determining factor here. Eligibility for a treatment depends upon the performance status of the patient - which could mean, for example, that a particular older patient could tolerate a certain treatment better than another younger patient might be able to.

As we said in our submission, CCC believes that colorectal cancer patients should have equal access to the treatments that are right for them. Furthermore, we believe that both oxaliplatin and capecitabine offer patients significant distinct benefits and, consequently, should be made as widely available as possible.

Best wishes and thanks.

Ian

Ian Beaumont  
Director of Press, PR and Public Affairs  
Colon Cancer Concern